MicroStrategy
MSTR
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
Meritage Homes
MTH
US Stock MarketDetailed Quotes
CARA Cara Therapeutics
- 0.423
- +0.014+3.35%
Close Dec 20 16:00 ET
- 0.409
- -0.014-3.24%
Post 19:59 ET
23.18MMarket Cap-0.24P/E (TTM)
0.460High0.340Low5.36MVolume0.344Open0.409Pre Close2.16MTurnover11.45%Turnover RatioLossP/E (Static)54.86MShares1.15052wk High32.51P/B19.77MFloat Cap0.22652wk Low--Dividend TTM46.79MShs Float29.647Historical High--Div YieldTTM29.37%Amplitude0.226Historical Low0.403Avg Price1Lot Size
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.
Cara Therapeutics Stock Forum
Off course I would sell over 2000 shares of cara before she rockets up. Off course..
1. NFA
2. Do not open position without chart confirmation, indicators, momentum.
3. Check current shorts availability on FINTEL.io
4. Scale out and secure profits
5. Always remember shorts include dark pools.
6. Most importantly, don’t blame for your losses. I already give watchlist and stock education. The ball is on you.
7. I DO NOT give buy or sell advice
8. COH (cash on hand); AH (after hours): RTH (regular trading hours)
$Currenc Group (CURR.US)$ Despac Sk...
CSL Limited Reports 13.5% Stake in Cara Therapeutics Inc as of Oct 23 - SEC Filing
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
Cara Therapeutics announced disappointing results from Part A of their KOURAGE-1 study, evaluating oral difelikefalin for notalgia paresthetica (NP). The drug did not show meaningful clinical benefit over placebo at any dose, leading the company to discontinue the clinical program in NP. The Phase 2/3 trial involved 214 patients, and despite the...
CERo Therapeutics, Inc. Presents Encouraging Preclinical Data for AML on CER-1236 at Stanford Drug Discovery Symposium Highlighting Tumor Elimination and Manufacturing Attributes30/04/2024 09:00AM ET
SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (NASDAQ:CERO) ("CERo") an innovative immunotherapy company seeking to advance the next generation of engineered T cell therapeutics that employ phagocytic a...
No comment yet